• The DNA sequence is identical among the cells of all tissue types

  • But each type of tissue has its unique methylation pattern

    Methyl group (CH3)

  • Cancer tissue also has a unique methylation pattern that let us distinguish it from healthy tissue

    Methyl group (CH3)

    EpiCheck® unique cancer biomarker

Using DNA methylation patterns for cancer detection:

Methylation of the DNA is a set of ‘switches’ that activate or deactivate specific genes in order to allow different cell types to perform their role. It is therefore a powerful tool to distinguish between cell types. Cancer cells show changes in methylation pattern in relation to healthy cells, and if one could “read” these methylation changes against a large background of normal signal coming from healthy cells, one would be able to detect the presence of tumors in body fluids, such as urine and blood. This is exactly what Nucleix does. Nucleix has developed a method to read these codes and detect them with extremely high sensitivity. DNA Methylation changes provides an optimal biomarker due to the:

  • High stability of DNA molecules
  • Large amount of information in methylation patterns
  • DNA extraction and analysis includes simple and standard lab work

Nucleix provides the best-in-class methylation analysis through its state-of-the-art technology:

  • A bioinformatics tool enabling rapid and systematic development of biomarker panels for a wide range of clinical tasks.
  • A proprietary technology for a simple, low cost clinical assay with a signal to noise ratio that is better than 1:150,000 (that is identifying one methylation change in a background of 150,000 normal molecules).

Our Advantage

  • No DNA quantification
  • Multiplexing of markers (15 in our 1st product)  to ensure high sensitivity and specificity
  • Test works with a wide range of DNA quantities, starting at 10ng
  • Noise immunity- very sensitive assay and analysis method
  • Measurable result on the current status using our EpiScore – Enables follow up to detect trends in disease evolution
  • We own our markers
  • Technology can work on various PCRs and future platforms (e.g. NGS)